We are live on ! Find out more
TXG icon

10x Genomics
TXG

314 hedge funds and large institutions have $6.29B invested in 10x Genomics in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 135 increasing their positions, 72 reducing their positions, and 96 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 135 | Existing positions reduced: 72

1.43% more ownership

Funds ownership: 87.32% → 88.75% (+1.4%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

14% less funds holding

Funds holding: 365 → 314 (-51)

35% less call options, than puts

Call options by funds: $20.5M | Put options by funds: $31.7M

47% less capital invested

Capital invested by funds: $11.9B → $6.29B (-$5.58B)

48% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 96

Holders
314
Holders Change
-51
Holders Change %
-13.97%
% of All Funds
4.95%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
135
Reduced
72
Closed
96
Calls
$20.5M
Puts
$31.7M
Net Calls
-$11.2M
Net Calls Change
-$3.96M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$389M
2
Sands Capital Management
Sands Capital Management
Virginia
+$134M
3
BlackRock
BlackRock
New York
+$99.6M
4
AIM
ARK Investment Management
Florida
+$63.9M
5
1WCM
12 West Capital Management
New York
+$45M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$268M
2
DCP
D1 Capital Partners
New York
-$239M
3
William Blair Investment Management
William Blair Investment Management
Illinois
-$159M
4
JCM
JS Capital Management
New York
-$80.5M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$68.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
326
Tributary Capital Management
Nebraska
– -$1.07M -7,200 Closed
CPM
327
Connective Portfolio Management
New York
– -$1.06M -7,000 Closed
HighTower Advisors
328
HighTower Advisors
Illinois
– -$847K -5,707 Closed
MLICM
329
Metropolitan Life Insurance Company (MetLife)
New York
– -$838K -5,624 Closed
Citadel Advisors
330
Citadel Advisors
Florida
– -$491K -5,616 Closed
William Blair & Company
331
William Blair & Company
Illinois
– -$789K -5,297 Closed
ACM
332
AlphaCrest Capital Management
New York
– -$772K -5,182 Closed
PP
333
Paloma Partners
Connecticut
– -$767K -5,151 Closed
AIM
334
Aigen Investment Management
New York
– -$675K -4,765 Closed
AGM
335
Alpine Global Management
New York
– -$678K -4,551 Closed
SCM
336
Silvant Capital Management
Georgia
– -$626K -4,202 Closed
Squarepoint
337
Squarepoint
New York
– -$622K -4,175 Closed
CWM
338
Congress Wealth Management
Massachusetts
– -$548K -3,679 Closed
WIS
339
Wright Investors Service
Connecticut
– -$504K -3,384 Closed
JF
340
Jump Financial
Illinois
– -$499K -3,344 Closed
CB
341
Commerce Bank
Missouri
– -$480K -3,225 Closed
TSS
342
Two Sigma Securities
New York
– -$277K -3,162 Closed
Man Group
343
Man Group
United Kingdom
– -$459K -3,085 Closed
GAM
344
Griffin Asset Management
New York
– -$424K -2,848 Closed
MMA
345
Miracle Mile Advisors
California
– -$409K -2,749 Closed
MYAM
346
Meiji Yasuda Asset Management
Japan
– -$369K -2,480 Closed
ASN
347
Advisory Services Network
Georgia
– -$351K -2,357 Closed
ProShare Advisors
348
ProShare Advisors
Maryland
– -$343K -2,300 Closed
BRWA
349
B. Riley Wealth Advisors
Florida
– -$314K -2,106 Closed
APG
350
Abacus Planning Group
South Carolina
– -$313K -2,100 Closed
12 13
14
15 16

TXG Hedge Fund Activity: Q1 2022 in Review

314 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2022, worth a combined $6.29B — down 47% from $11.9B a quarter earlier.

Sellers outnumbered buyers: 96 funds closed out of TXG and 50 opened new positions — a net loss of 46 holders — while 72 trimmed existing stakes and 135 added.

The largest buyer was Morgan Stanley, adding an estimated $389M. The largest seller was Fidelity Investments, cutting an estimated $268M.

  • 314 institutional investors held 10x Genomics (TXG) as of Q1 2022, down from 365 in Q4 2021.
  • Funds reported $6.29B of 10x Genomics stock for Q1 2022, down 47% quarter-over-quarter.
  • 50 funds opened new 10x Genomics positions in Q1 2022 and 96 closed out, a net change of -46 holders.
  • The largest 10x Genomics buyer in Q1 2022 was Morgan Stanley, an estimated $389M added.
  • The largest 10x Genomics seller in Q1 2022 was Fidelity Investments, an estimated $268M sold.

Based on aggregated 13F filings for Q1 2022.